Skip to main content
TipRanks
Go Ultimate75% OFF

Bio-Rad Laboratories (BIO) Stock Price & Analysis

931 Followers

BIO Stock Chart & Stats

$366.36-$4.12(-1.11%)
At close: 4:00 PM EST
$350$375Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$364.11 - $373.50
52-Week Range
$236.73 - $396.23
Previous Close
$370.48
Volume
N/A
Average Volume (3M)
244.60K
Market Cap
$9.86B
Enterprise Value
$9.87B
Total Cash (Recent Filing)
$1.66B
Total Debt (Recent Filing)
$1.36B
Price to Earnings (P/E)
9.6
Beta
0.81
Next Earnings
Feb 18, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet

Bio-Rad’s low leverage and substantial equity base provide financial resilience and reduce refinancing risk. This structure gives management flexibility to continue investing in innovation, support operations through uneven demand, and pursue measured acquisitions without relying heavily on additional debt.

Diagnostics And DdPCR Momentum

Growth in Clinical Diagnostics and strong ddPCR instrument adoption show that Bio-Rad retains competitive product momentum in important workflows. Installed instruments can support recurring reagent and consumable demand, while portfolio expansion and workflow improvements may extend adoption over multiple quarters.

Margin And Cash-improvement Program

Reaffirmed cash-flow guidance and planned restructuring savings support a durable improvement in operating efficiency. If execution continues, lower costs and better productivity should strengthen cash generation and create additional capacity for innovation, portfolio development, and disciplined capital allocation.

Bears Say

Weak Revenue Outlook

The outlook indicates that overall demand remains fragile, particularly in Life Science, limiting near-term revenue visibility and operating leverage. Negative-to-flat growth also makes it harder to absorb fixed costs, sustain margin expansion, and build confidence that the recovery will persist.

China Pricing And Regulatory Pressure

China’s preference for domestic suppliers and updated reimbursement-related guidelines create a structural pricing and revenue headwind in in-vitro diagnostics. These pressures can reduce realized pricing, constrain customer demand, and make future growth less predictable in an important regional market.

Earnings Volatility And Charges

Large swings between losses and profits reduce confidence in the durability of Bio-Rad’s earnings power, even with a recent rebound. Inconsistent operating profitability can complicate planning, weaken returns on the capital base, and leave results more exposed to changes in demand and restructuring activity.

Bio-Rad Laboratories News

BIO FAQ

What was Bio-Rad Laboratories’s price range in the past 12 months?
Bio-Rad Laboratories lowest stock price was $236.73 and its highest was $396.23 in the past 12 months.
What is Bio-Rad Laboratories’s market cap?
Bio-Rad Laboratories’s market cap is $9.86B.
When is Bio-Rad Laboratories’s upcoming earnings report date?
Bio-Rad Laboratories’s next earnings report is estimated for Feb 18, 2027 (not yet confirmed), which is in 94 days.
How were Bio-Rad Laboratories’s earnings last quarter?
Bio-Rad Laboratories released its earnings results on Nov 04, 2026. The company reported $2.65 earnings per share for the quarter, beating the consensus estimate of $2.226 by $0.424.
Is Bio-Rad Laboratories overvalued?
According to Wall Street analysts Bio-Rad Laboratories’s price is currently Undervalued.
Does Bio-Rad Laboratories pay dividends?
Bio-Rad Laboratories does not currently pay dividends.
What is Bio-Rad Laboratories’s EPS estimate?
Bio-Rad Laboratories’s EPS estimate is 2.83.
How many shares outstanding does Bio-Rad Laboratories have?
Bio-Rad Laboratories has 21,832,130 shares outstanding.
What happened to Bio-Rad Laboratories’s price movement after its last earnings report?
Bio-Rad Laboratories reported an EPS of $2.65 in its last earnings report, beating expectations of $2.226. Following the earnings report the stock price went down -2.892%.
Which hedge fund is a major shareholder of Bio-Rad Laboratories?
Hedge funds hold Bio-Rad Laboratories shares: the largest hedge-fund position in Bio-Rad Laboratories is 72,219,532 shares, and hedge funds decreased their holdings by 120.7K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology